Somewhat Positive Media Coverage Somewhat Unlikely to Impact Agios Pharmaceuticals (AGIO) Share Price
News articles about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.1314212646402 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:
- Stocks Showing Improving Market Leadership: Agios Pharmaceuticals Earns 81 RS Rating (finance.yahoo.com)
- Agios Gears Up Pipeline To Create Future Value – Seeking Alpha (seekingalpha.com)
- Agios Outlines Key 2018 Priorities Expanding Clinical and Research Programs to Drive Long Term Value – GlobeNewswire (press release) (globenewswire.com)
- BRIEF-Agios Outlines Key 2018 Priorities Expanding Clinical And Research Programs To Drive Long Term Value (reuters.com)
A number of equities research analysts have recently weighed in on the stock. Credit Suisse Group raised their price objective on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Oppenheimer restated a “buy” rating and issued a $83.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, December 11th. Canaccord Genuity set a $90.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 12th. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price objective on the stock in a report on Tuesday. Finally, Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $75.00.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm had revenue of $11.35 million for the quarter, compared to analyst estimates of $10.85 million. During the same period last year, the business earned ($1.63) EPS. Agios Pharmaceuticals’s revenue for the quarter was up 26.4% compared to the same quarter last year. research analysts forecast that Agios Pharmaceuticals will post -6.59 EPS for the current year.
In related news, Director Lewis Clayton Jr. Cantley sold 3,838 shares of Agios Pharmaceuticals stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $59.37, for a total transaction of $227,862.06. Following the sale, the director now directly owns 80,851 shares in the company, valued at approximately $4,800,123.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total transaction of $383,100.00. The disclosure for this sale can be found here. Insiders have sold a total of 29,130 shares of company stock worth $1,844,260 over the last quarter. 5.43% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/01/12/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-agios-pharmaceuticals-agio-share-price.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.